Ontology highlight
ABSTRACT:
PROVIDER: PRJNA839375 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR19268426_1.fastq.gz | Fastqsanger.gz | |||
| SRR19268426_2.fastq.gz | Fastqsanger.gz | |||
| SRR19268427_1.fastq.gz | Fastqsanger.gz | |||
| SRR19268427_2.fastq.gz | Fastqsanger.gz | |||
| SRR19268428_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 32 |
Similar Datasets
Project description:DNA methylation data from common marmosets (Callithrix jacchus) profiled on the mammalian methylation array (HorvathMammalMethylChip40) which focuses on highly conserved CpGs across mammalian species. Rapamycin study in a subset of animals.
2023-08-05 | GSE190663 | GEO
Project description:Whole genome sequencing and analysis of common marmosets (Callithrix jacchus)
| PRJNA955237 | ENA
Project description:The common marmoset (marmoset; Callithrix jacchus) shows anatomical and physiological features that are in common with humans. Establishing induced pluripotent stem cells (iPSCs) from marmosets holds promise for enhancing the utility of the animal model for biomedical and preclinical studies. However, in spite of the presence of some previous reports on marmoset iPSCs, the reprogramming technology in marmosets is still under development. In particular, the efficacy of RNA-based reprogramming has not been thoroughly investigated. In this study, we attempted RNA-based reprogramming for deriving iPSCs from marmoset fibroblasts. Although we failed to derive iPSC colonies from marmoset fibroblasts by using a conventional RNA-based reprogramming method previously validated in human fibroblasts, we succeeded in deriving colony-forming cells with a modified induction medium supplemented with a novel set of small molecules. Importantly, following one-week culture of the colony-forming cells in conventional embryonic stem cell (ESC) medium, we obtained iPSCs which express endogenous pluripotent markers and show a differentiation potential into all three germ layers. Taken together, our results indicate that RNA-based reprogramming, which is valuable for deriving transgene-free iPSCs, is applicable to marmosets.
2020-06-12 | GSE152259 | GEO
Project description:Fragile X syndrome (FXS) is a monogenic cause of intellectual disability, developmental delay, and autism spectrum disorder (ASD), estimated to occur in 1 in 5,000 males and 1 in 4,000 to 1 in 8,000 females. It is caused by a CGG trinucleotide repeat expansion in the 5’ untranslated region of the fragile X messenger ribonucleoprotein 1 (FMR1) gene located at Xq27.3. A full mutation, greater than 200 CGG repeats, leads to silencing of the FMR1 gene and consequent loss of its product, the fragile X messenger ribonucleoprotein (FMRP). We generated FMR1 mutant common marmosets (Callithrix jacchus) using the CRISPR/Cas9 system and performed proteomic analysis of their neonatal forebrains to identify molecular changes associated with FMR1 deficiency. We analyzed samples from two wild-type (WT) and two FMR1 mutant marmosets.
2025-07-16 | PXD066203 | JPOST Repository
Project description:We report the discovery of six novel miRNAs expressed by Herpesvirus saimiri (strain A11). These miRNAs are generated by a non-canonical biogenesis pathway that does not require the Microprocessor complex. Examination of one sample prepared from common marmoset (Callithrix jacchus) T cells latently infected with Hespesvirus saimiri (strain A11).
2011-09-21 | E-GEOD-31065 | biostudies-arrayexpress
Project description:The postsynaptic density (PSD) is a protein condensate composed of ~1,000 proteins beneath the postsynaptic membrane of excitatory synapses. The number, shape, and plasticity of synapses are altered during development. However, the dynamics of synaptic protein composition across development have not been fully understood. Here we show alterations of PSD protein composition in mouse and primate brains during development. Proteins involved in synapse regulation are enriched in the differentially expressed (288 decreased and 267 increased) proteins on mouse PSD after a 2-week-old, which may be involved in changes of synaptic signal transduction. We find that the changes in PSD protein abundance in mouse brains correlate with gene expression levels in postnatal mice and perinatal primates. Proteome analysis of PSD from developing common marmosets (Callithrix jacchus) shows that the changes of PSD composition in mouse brain after 2-week-old occur in the marmoset brain mainly during the neonatal period and continue until adulthood. We also describe the changes of PSD proteome at the late developmental stage of marmoset, which may be involved in synaptic pruning observed in primate brains. The maturation of PSD composition is likely defective in autism spectrum disorder (ASD). Our results provide a comprehensive architecture of the remodeling of PSD composition across development, which may explain the molecular basics of synapse maturation and the pathology of psychiatric disorders, such as ASD.
2024-01-17 | PXD048549 | Pride
Project description:Callithrix jacchus (common marmoset) genome assembly , mCalJac1
| PRJNA560230 | ENA
Project description:Callithrix jacchus Transcriptome or Gene expression
| PRJNA397900 | ENA
Project description:Alzheimer’s disease (AD) is the first leading cause of dementia which afflicts tens of millions of people worldwide. Despite many scientific progresses to dissect the molecular basis of AD from studies on various mouse models, it has been suffered from evolutionary species differences between mice and humans. Here, we report generation of a non-human primate, common marmoset (marmoset; Callithrix jacchus) model that ubiquitously expresses Amyloid-beta precursor protein (APP) transgenes with the Swedish (KM670/671NL) and Indiana (V717F) mutations. We generated two female transgenic marmosets (TG1 and TG2), whose transgene integration was thoroughly investigated by genomic PCR, whole genome sequencing (WGS) and Fluorescence in situ hybridization (FISH) analyses. Using the reprogramming technology, we confirmed the validity of the transgene expression in induced neurons in vitro. Moreover, we discovered structural changes in specific brain regions of transgenic marmosets by magnetic resonance imaging (MRI) analysis, including in the entorhinal cortex and hippocampus. In postmortem histological analysis, we detected increased Aβ plaque formation in the TG1 cerebrum at the age of 7 years, although evident neuronal loss or glial inflammation was not observed. Thus, this study summarizes our attempt to establish a non-human primate model of AD, which may be beneficial for drug development and further disease modeling in combination with other genetically engineered models.
2022-03-01 | GSE194005 | GEO
Project description:Alzheimer’s disease (AD) is the first leading cause of dementia which afflicts tens of millions of people worldwide. Despite many scientific progresses to dissect the molecular basis of AD from studies on various mouse models, it has been suffered from evolutionary species differences between mice and humans. Here, we report generation of a non-human primate, common marmoset (marmoset; Callithrix jacchus) model that ubiquitously expresses Amyloid-beta precursor protein (APP) transgenes with the Swedish (KM670/671NL) and Indiana (V717F) mutations. We generated two female transgenic marmosets (TG1 and TG2), whose transgene integration was thoroughly investigated by genomic PCR, whole genome sequencing (WGS) and Fluorescence in situ hybridization (FISH) analyses. Using the reprogramming technology, we confirmed the validity of the transgene expression in induced neurons in vitro. Moreover, we discovered structural changes in specific brain regions of transgenic marmosets by magnetic resonance imaging (MRI) analysis, including in the entorhinal cortex and hippocampus. In postmortem histological analysis, we detected increased Aβ plaque formation in the TG1 cerebrum at the age of 7 years, although evident neuronal loss or glial inflammation was not observed. Thus, this study summarizes our attempt to establish a non-human primate model of AD, which may be beneficial for drug development and further disease modeling in combination with other genetically engineered models.
2022-03-01 | GSE192674 | GEO